Manila Bulletin
COVID-19 vaccines expected to get full authorization from PH FDA by 2022
The Philippine Food and Drug Administration (FDA) is aiming to grant full marketing authorization for several COVID-19 vaccines by the first quarter of 2022.
This full approval signifies that the FDA has gathered sufficient scientific evidence proving the vaccines' benefits outweigh their risks and that they can be manufactured reliably and safely.
Currently, nine vaccine brands have emergency use authorization (EUA) in the Philippines, including Pfizer-BioNTech, AstraZeneca, and Sinovac.
Under an EUA, only the government can procure vaccines, though private companies can acquire them through tripartite agreements.
While the US FDA granted Pfizer full authorization in August, Pfizer has not yet applied for full approval in the Philippines.
🤖
This story was generated by AI to help you understand the key points. For more detailed coverage, please see the news articles from trusted media outlets below.
News Sources
See how different news organizations are covering this story. Below are the original articles from various Philippine news sources that contributed to this summary.
The Food and Drug Administration (FDA) has authorized four COVID-19 vaccine brands – Pfizer-BioNTech, AstraZeneca, and Sinovac – to be used as homologous (same brand) additional doses.
Read more →
The Philippines has granted emergency use authorization (EUA) for Novavax's COVID-19 vaccine, Covovax, for individuals aged 18 and above.
Read more →
The Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for Novavax's COVID-19 vaccine, Covovax.
Read more →
The Philippine FDA approved on Nov. 17 the country's coronavirus disease (COVID-19) vaccine mix-and-match trials.
+1
Read more →
The Philippines received 1,306,000 doses of Moderna and 609,570 doses of Pfizer-BioNTech COVID-19 vaccines on November 19, 2021.
Read more →